AZNAstraZenecaRunning, no new patients
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
Triple Negative Breast Neoplasms
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 243 (final count)
- Started
- Dec 21, 2018
- Main results expected
- Nov 29, 2024
- Fully finished
- Feb 26, 2027
- Results posted
- Feb 2, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Dose Limiting Toxicity (DLT) Events
Measured over: From the time of first dose until completion of the first cycle (28 days for Arms 2-5, 21 days for Arms 6-7 (no safety run-in for Arms 1 and 8))
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03742102 · record last updated 2026-08-04 · checked 2026-11-09 15:47 UTC